Volume 98, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Cirrhosis is the dominant cause of portal hypertension globally but may be overshadowed by hepatosplenic schistosomiasis (HSS) in the tropics. In Zambia, schistosomiasis seroprevalence can reach 88% in endemic areas. Bacterial translocation (BT) drives portal hypertension in cirrhosis contributing to mortality but remains unexplored in HSS. Rifaximin, a non-absorbable antibiotic may reduce BT. We aimed to explore the influence of rifaximin on BT, inflammation, and fibrosis in HSS. In this phase II open-label trial (ISRCTN67590499), 186 patients with HSS in Zambia were evaluated and 85 were randomized to standard care with or without rifaximin for 42 days. Changes in markers of inflammation, BT, and fibrosis were the primary outcomes. BT was measured using plasma 16S rRNA, lipopolysaccharide-binding protein, and lipopolysaccharide, whereas hyaluronan was used to measure fibrosis. Tumor necrosis factor receptor 1 (TNFR1) and soluble cluster of differentiation 14 (sCD14) assessed inflammation. 16S rRNA reduced from baseline (median 146 copies/µL, interquartile range [IQR] 9, 537) to day 42 in the rifaximin group (median 63 copies/µL, IQR 12, 196), < 0.01. The rise in sCD14 was lower ( < 0.01) in the rifaximin group (median rise 122 ng/mL, IQR-184, 783) than in the non-rifaximin group (median rise 832 ng/mL, IQR 530, 967). TNFR1 decreased ( < 0.01) in the rifaximin group (median -39 ng/mL IQR-306, 563) but increased in the non-rifaximin group (median 166 ng/mL, IQR 3, 337). Other markers remained unaffected. Rifaximin led to a reduction of inflammatory markers and bacterial 16S rRNA which may implicate BT in the inflammation in HSS.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. Shaker Y, Samy N, Ashour E, , 2014. Review article hepatobiliary schistosomiasis. J Clin Transl Hepatol 2: 212216.
  2. Sinkala E, Kapulu MC, Besa E, Zyambo K, Chisoso NJ, Foster GR, Kelly P, , 2015. Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis. Liver Int 36: 145150.
  3. Ibrahim SZ, Arbab BM, Suleiman SH, Abdelwahab O, Hassan MA, , 2010. The natural history of bleeding oesophageal varices in patients with schistosomal portal hypertension. Khartoum Med J 3: 385392.
  4. Rajekar H, Vasishta RK, Chawla YK, Dhiman RK, , 2011. Noncirrhotic portal hypertension. J Clin Exp Hepatol 1: 94108.
  5. Kibiki GS, Drenth JPH, Nagengast JMF, , 2004. Hepatosplenic schistosomiasis: a review. East Afr Med J 81: 480485.
  6. Chipeta J, Mwansa J, Kachimba JS, , 2009. Schistosomiasis disease burden in Zambian children: time for affirmative action is now. Med J Zambia 36: 15.
  7. Mutengo MM, Mwansa JCL, Mduluza T, Sianongo S, Chipeta J, , 2014. High Schistosoma mansoni disease burden in a rural district of western Zambia. Am J Trop Med Hyg 91: 965972.
  8. Payne L, Turner-Moss E, Mutengo M, Asombang AW, Kelly P, , 2013. Prevalence of schistosome antibodies with hepatosplenic signs and symptoms among patients from Kaoma, western province, Zambia. BMC Res Notes 6: 344.
  9. Bellot P, Francés R, Such J, , 2013. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 33: 3139.
  10. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG, , 2009. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 29: 992999.
  11. Balzan S, De Almeida Quadros C, De Cleva R, Zilberstein B, Cecconello I, , 2007. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol 22: 464471.
  12. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ, , 1999. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104: 12231233.
  13. Gou Y-Z, Lian J-Q, Nie Q-H, , 2006. Bacterial translocation and its consequences in patients with liver cirrhosis. Chin J Hepatol 14: 796797.
  14. Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Jose S, Jaime B, , 2010. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 52: 20442052.
  15. Fukui H, , 2015. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol 7: 425442.
  16. Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, Tachibana M, Kubota H, Kohno H, Harada T, , 2000. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 31: 11071114.
  17. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M, , 2011. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review. Aliment Pharmacol Ther 34: 509518.
  18. Koutsounas I, , 2015. Markers of bacterial translocation in end-stage liver disease. World J Hepatol 7: 2264.
  19. Onguru D, Liang Y, Griffith Q, Nikolajczyk B, Mwinzi P, Ganley-Leal L, , 2011. Human schistosomiasis is associated with endotoxemia and toll-like receptor 2- and 4-bearing B cells. Am J Trop Med Hyg 84: 321324.
  20. Ferraz AAB, Campos JM, Júnior JGCDA, De Albuquerque AC, Ferraz EM, , 2005. Gut bacterial translocation and postoperative infections: a prospective study in schistosomotic patients. Surg Infect (Larchmt) 6: 197201.
  21. Lutz P, Parcina M, Bekeredjian-Ding I, Nischalke HD, Nattermann J, Sauerbruch T, Hoerauf A, Strassburg CP, Spengler U, , 2014. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One 9: e93909.
  22. Bremer E, , 2013. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol 2013: 371854.
  23. Nathan BM, 2010. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 10711081.
  24. Taylor DN, McKenzie R, Durbin A, Carpenter C, Haake R, Bourgeois AL, , 2008. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 52: 11791181.
  25. Xu D, Gao J, Gillilland M, 3rd Wu X, Song I, Kao JY, Owyang C, , 2014. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterol 146: 484496.
  26. Koo LH, Sabounchi S, Huang DB, DuPont HL, , 2012. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 5: 3141.
  27. Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP, , 2015. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther 41: 3945.
  28. Brenner SA, Zacheja S, Sch M, Bischoff SC, , 2014. Soluble CD14 is essential for lipopolysaccharide-dependent activation of human intestinal mast cells from macroscopically normal as well as Crohn’s disease tissue. Immunology 143: 174183.
  29. Marchetti G, Tincati C, Silvestri G, , 2013. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 26: 218.
  30. López M, Figueras F, Coll O, Goncé A, Hernández S, Loncá M, Vila J, Gratacos E, Palacio M, , 2015. Inflammatory markers related to microbial translocation among HIV-infected pregnant women: a risk factor of preterm delivery. J Infect Dis 213: 343350.
  31. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, Wanke CA, Ward DH, , 2015. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis 211: 1927.
  32. Berbée JFP, Coomans CP, Westerterp M, Romijn JA, Havekes LM, Rensen PCN, , 2010. Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix. J Lipid Res 51: 19431952.
  33. Tarrats N, Moles A, Morales A, García-Ruiz C, Fernández-Checa JC, Marí M, , 2011. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology 54: 319327.
  34. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F, , 2013. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 8: 18.
  35. Stehle JR, Leng X, Kitzman DW, Nicklas BJ, Kritchevsky SB, High KP, , 2012. Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. J Gerontol A Biol Sci Med Sci 67: 12121218.
  36. Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D, , 1997. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 4: 113116.
  37. Marinho CC, Bretas T, Voieta I, De Queiroz LC, Ruiz-guevara R, Teixeira AL, Antunes CM, Prata A, Lambertucci JR, , 2010. Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for Schistosomiasis mansoni: a field-based study in Brazil. Mem Inst Oswaldo Cruz, Rio 105: 471478.
  38. Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang Z-D, DuPont HL, Shah VH, , 2012. Intestinal decontamination inhibits TLR4 dependent fibronectin mediated crosstalk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 56: 893899.
  39. Arthur L, Leite C, , 2013. Relationship between splenomegaly and hematologic findings in patients with hepatosplenic schistosomiasis. Rev Bras Hematol Hemoter 35: 332336.
  40. Funakoshi N, Ségalas-largey F, Duny Y, Oberti F, Valats J, Bismuth M, Daures JP, Blanc P, , 2010. Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 16: 59825992.

Data & Media loading...

  • Received : 10 Aug 2017
  • Accepted : 09 Oct 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error